WALTHAM, Mass.--(BUSINESS WIRE)--Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, today presented new clinical data from its Phase 1 clinical study of ...
Upstream Bio (UPB), CeriBell (CBLL) and CAMP4 Therapeutics (CAMP) have set terms for their proposed initial public offerings. Upstream (UPB) said in its latest SEC filing that it was looking at ...
Upstream Bio's sole drug, verekitug, targets severe asthma, CRSwNP, and COPD, with promising early phase 2 data expected in 2025 and 2026. Verekitug, a TSLP receptor inhibitor, shows higher efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback